Ensysce Biosciences, Inc.
ENSC Healthcare Biotechnology
Ensysce Biosciences, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $5.1 million, down 2.75% from fiscal 2024. In the quarter to June 2026, revenue fell 15.1%, EPS grew 74.7% and free cash flow grew 27.5%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
Follow ENSC
Ensysce Biosciences, Inc. (ENSC) EV/Sales
As of 16 October 2026, Ensysce Biosciences, Inc. (ENSC) trades at a EV/Sales of 1.5×. Over the past ten years it has ranged from −0.9× (December 2022) to 81.3× (July 2021); the current reading is higher than 79% of that period. That is below the Biotechnology industry median of 9.2× and below the Healthcare sector median of 3.4×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2025 | −0.2× | — |
| FY2024 | 0.6× | (41.84%) |
| FY2023 | 1.0× | — |
| FY2022 | −0.2× | — |
| FY2021 | 24.8× | — |
| FY2020 | 0.0× | — |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Jun 2026 | 0.9× | 8.96% |
| Mar 2026 | 0.8× | — |
| Dec 2025 | −0.2× | — |
| Sep 2025 | 1.3× | 181.39% |
| 21 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| ASBP Aspire-Lakewood Holdings, Inc. compare | −2.7× |
| ACTU Actuate Therapeutics, Inc. compare | n/m |
| AEON AEON Biopharma, Inc. compare | n/m |
| CLRB Cellectar Biosciences, Inc. compare | n/m |
| INAB IN8bio, Inc. compare | n/m |
| PASG Passage Bio, Inc. compare | n/m |
| PTN Palatin Technologies, Inc. compare | 0.7× |
| ENSC Ensysce Biosciences, Inc. | 1.5× |
| PLUR Pluri Inc. compare | 29.0× |
| Biotechnology industry median | 9.2× |
| Healthcare sector median | 3.4× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)